CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO John Climaco will present at the Q2 Virtual Investor Summit at 12:30 p.m. ET on Tuesday, May 18. In addition to the presentation, CNS … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Q2 Virtual Investor Summit”
During Phase 1 trials, Berubicin showed 44% of patients experienced a clinical benefit of stable disease or better, one being cancer-free after 14 years, and two patients reporting significant tumor reduction (up to 80%) Additional research to be conducted by sublicensee partner WPD Pharmaceuticals, Inc. in Poland, including the first-ever pediatric trial The glioblastoma multiforme … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) on Track to Begin Potentially Pivotal Phase 2 GBM Trial This Quarter for Berubicin”
CNS Pharmaceuticals (NASDAQ: CNSP) is working to determine the efficacy of its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive type of brain cancer for which there is currently no cure. Promising results were demonstrated when another company completed a small Phase 1 trial well over a decade ago in … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Start Potentially Pivotal Berubicin Trial”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin”
CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its cancer-fighting potential. Berubicin was the subject of a Phase 1 safety trial conducted by Reata … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial”
Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosed A recent study by the Washington University School of Medicine found that the length of survivability appeared to improve when the standard chemotherapy regimen was given … Continue reading “Patients with Incurable Brain Cancers Find New Hope in University Study, Upcoming CNS Pharmaceuticals (NASDAQ: CNSP) Clinical Trial”
GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancy Potentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1 2021 The company is continuing its pre-clinical work on WP1244 during 2021 and 2022 CNS Pharmaceuticals participated in two virtual … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) New Investor Presentation Shows Value-Added Milestones for Berubicin in 2021”
CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that the Wroclaw, Poland-based Lower Silesian Medical Chamber Ethics Committee gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), the company’s sublicensee in Europe and Asia for its lead drug candidate, Berubicin, a positive opinion for its WPD-201 Clinical Trial Protocol. The protocol will be used in the planned forthcoming … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Continues to Advance Toward Clinical Trials”
Brain cancer drug developer CNS Pharmaceuticals is finalizing preparations to begin March enrollment of patients in its potentially pivotal Phase 2 trial evaluating its promising lead candidate, Berubicin, for the overall survival improvement of glioblastoma (“GBM”) patients Glioblastomas are a type of brain cancer that have continued to elude effective therapy over the past century … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Begin Enrolling Brain Cancer Drug Trial Participants”
CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco will be presenting at the inaugural Emerging Growth Virtual Conference. Scheduled for March 17–18, the virtual conference is presented by M Vest LLC and Maxim Group LLC. The conference agenda includes roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A’s, and presentations … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in First-Ever Emerging Growth Virtual Conference”
